Robert A. Mitchell

Robert A. Mitchell

Auto-generated profile, based on publicly available information

Robert A. Mitchell

Department of Surgery, Division of Immunotherapy, University of Louisville School of Medicine, Louisville, KY 40202, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Science Advances
Verified
Journal Article
Open access
JNJordan T. Noe
Jordan T. Noe
BRBeatriz E. Rendon
Beatriz E. Rendon
AGAnne E. Geller
Anne E. Geller
LCLindsey R. Conroy
Lindsey R. Conroy
SMSamantha M. Morrissey
Samantha M. Morrissey
RMRobert A. Mitchell
Robert A. Mitchell
Macrophages use mitochondrial lactate metabolism for ACLY-dependent histone acetylation, immune suppression, and tumor progression.

5 January 2023 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
CDChuanlin Ding
Chuanlin Ding
RSRejeena Shrestha
Rejeena Shrestha
XZXiaojuan Zhu
Xiaojuan Zhu
AGAnne E. Geller
Anne E. Geller
SWShouzhen Wu
Shouzhen Wu
JYJun Yan
Jun Yan

25 November 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JNJordan T. Noe
Jordan T. Noe
RMRobert A. Mitchell
Robert A. Mitchell
Initially identified as a T lymphocyte-elicited inhibitor of macrophage motility, macrophage migration inhibitory factor (MIF) has since been found to be expressed by nearly every immune cell type examined and overexpressed in most solid and hematogenous malignant cancers. It is localized to both extracellular and intracellular compartments and physically interacts with more than a dozen different cell surface and intracellular proteins. Although classically associated with and characterized as a mediator of pro-inflammatory innate immune responses, more recent studies demonstrate that, in malignant disease settings, MIF contributes to anti-inflammatory, immune evasive, and immune tolerant phenotypes in both innate and adaptive immune cell types. This review will summarize the studies describing MIF in tumor-specific innate and adaptive immune responses and attempt to reconcile these various pleiotropic functions in normal physiology.

15 March 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
KYKavitha Yaddanapudi
Kavitha Yaddanapudi
KPKalyani Putty
Kalyani Putty
BRBeatriz E Rendon
Beatriz E Rendon
GLGwyneth J. Lamont
Gwyneth J. Lamont
JFJonathan D. Faughn
Jonathan D. Faughn
RMRobert A Mitchell
Robert A Mitchell
Tumor stromal alternatively activated macrophages are important determinants of antitumor T lymphocyte responses, intratumoral neovascularization, and metastatic dissemination. Our recent efforts to investigate the mechanism of macrophage migration inhibitory factor (MIF) in antagonizing antimelanoma immune responses reveal that macrophage-derived MIF participates in macrophage alternative activation in melanoma-bearing mice. Both peripheral and tumor-associated macrophages (TAMs) isolated from melanoma bearing MIF-deficient mice display elevated proinflammatory cytokine expression and reduced anti-inflammatory, immunosuppressive, and proangiogenic gene products compared with macrophages from tumor-bearing MIF wild-type mice. Moreover, TAMs and myeloid-derived suppressor cells from MIF-deficient mice exhibit reduced T lymphocyte immunosuppressive activities compared with those from their wild-type littermates. Corresponding with reduced tumor immunosuppression and neo-angiogenic potential by TAMs, MIF deficiency confers protection against transplantable s.c. melanoma outgrowth and melanoma lung metastatic colonization. Finally, we report for the first time, to our knowledge, that our previously discovered MIF small molecule antagonist, 4-iodo-6-phenylpyrimidine, recapitulates MIF deficiency in vitro and in vivo, and attenuates tumor-polarized macrophage alternative activation, immunosuppression, neoangiogenesis, and melanoma tumor outgrowth. These studies describe an important functional contribution by MIF to TAM alternative activation and provide justification for immunotherapeutic targeting of MIF in melanoma patients.

14 September 2008 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MWMillicent Winner
Millicent Winner
JMJason Meier
Jason Meier
SZSwen Zierow
Swen Zierow
BRBeatriz E. Rendon
Beatriz E. Rendon
GCGregg V. Crichlow
Gregg V. Crichlow
RMRobert A. Mitchell
Robert A. Mitchell
Although chemokine and growth factor receptors are attractive and popular targets for cancer therapeutic intervention, structure-based targeting of the ligands themselves is generally not considered practical. New evidence indicates that a notable exception to this is macrophage migration inhibitory factor (MIF). MIF, an autocrine- and paracrine-acting cytokine/growth factor, plays a pivotal role in both the initiation and maintenance of neoplastic diseases. MIF possesses a nonphysiologic enzymatic activity that is evolutionarily well-conserved. Although small molecule antagonists of MIFs enzymatic active site have been reported to inhibit biological activities of MIF, universally high IC50s have limited their clinical appeal. Using a computational virtual screening strategy, we have identified a unique small molecule inhibitor that serves as a suicide substrate for MIF, resulting in the covalent modification of the catalytically active NH2-terminal proline. Our studies further reveal that this compound, 4-iodo-6-phenylpyrimidine (4-IPP), is ∼5× to 10× times more potent in blocking MIF-dependent catalysis and lung adenocarcinoma cell migration and anchorage-independent growth than the prototypical MIF inhibitor, ISO-1. Finally, using an in silico combinatorial optimization strategy, we have identified four unique congeners of 4-IPP that exhibit MIF inhibitory activity at concentrations 10× to 20× lower than that of parental 4-IPP. [Cancer Res 2008;68(18):7253–7]

9 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAnne E. Geller
Anne E. Geller
RSRejeena Shrestha
Rejeena Shrestha
MWMatthew Woeste
Matthew Woeste
HGHaixun Guo
Haixun Guo
XHXiaoling Hu
Xiaoling Hu
JYJun Yan
Jun Yan
Despite the remarkable success of immunotherapy in many types of cancer, pancreatic ductal adenocarcinoma has yet to benefit. Innate immune cells are critical to anti-tumor immunosurveillance and recent studies have revealed that these populations possess a form of memory, termed trained innate immunity, which occurs through transcriptomic, epigenetic, and metabolic reprograming. Here we demonstrate that yeast-derived particulate β-glucan, an inducer of trained immunity, traffics to the pancreas, which causes a CCR2-dependent influx of monocytes/macrophages to the pancreas that display features of trained immunity. These cells can be activated upon exposure to tumor cells and tumor-derived factors, and show enhanced cytotoxicity against pancreatic tumor cells. In orthotopic models of pancreatic ductal adenocarcinoma, β-glucan treated mice show significantly reduced tumor burden and prolonged survival, which is further enhanced when combined with immunotherapy. These findings characterize the dynamic mechanisms and localization of peripheral trained immunity and identify an application of trained immunity to cancer.